{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:15Z","timestamp":1740106935461,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grants of the National Cancer Center","award":["NCC 1410210"],"award-info":[{"award-number":["NCC 1410210"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00277-019-03891-9","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T12:28:47Z","timestamp":1577968127000},"page":"255-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Young-Woong","family":"Won","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2067","authenticated-orcid":false,"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Hee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Ho","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoungha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"issue":"32","key":"3891_CR1","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","volume":"29","author":"T Chisesi","year":"2011","unstructured":"Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V (2011) Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 29(32):4227\u20134233","journal-title":"J Clin Oncol"},{"issue":"8852","key":"3891_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"D Linch","year":"1993","unstructured":"Linch D, Goldstone A, McMillan A, Chopra R, Hudson GV, Winfield D, Hancock B, Moir D, Milligan D (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341(8852):1051\u20131054","journal-title":"Lancet"},{"issue":"9323","key":"3891_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M\u00fcller P, Kirchner H (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065\u20132071","journal-title":"Lancet"},{"issue":"4","key":"3891_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1634\/theoncologist.2009-0002","volume":"14","author":"JH Mendler","year":"2009","unstructured":"Mendler JH, Friedberg JW (2009) Salvage therapy in Hodgkin's lymphoma. Oncologist 14(4):425\u2013432","journal-title":"Oncologist"},{"issue":"6","key":"3891_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"N Bartlett","year":"2007","unstructured":"Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Johnson K, Van Besien K, Zelenetz A, Cheson B, Canellos G (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 18(6):1071\u20131079","journal-title":"Ann Oncol"},{"issue":"31","key":"3891_CR6","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY. 12. J Clin Oncol 32(31):3490\u20133496","journal-title":"J Clin Oncol"},{"issue":"8","key":"3891_CR7","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","volume":"51","author":"AK Gopal","year":"2010","unstructured":"Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 51(8):1523\u20131529","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3891_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 92(1):35\u201341","journal-title":"Haematologica"},{"issue":"4","key":"3891_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2012","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales M-A, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ (2012) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31(4):456\u2013460","journal-title":"J Clin Oncol"},{"issue":"19","key":"3891_CR10","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","volume":"118","author":"TA Fehniger","year":"2011","unstructured":"Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118(19):5119\u20135125","journal-title":"Blood"},{"issue":"5","key":"3891_CR11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB (2010) A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85(5):320\u2013324","journal-title":"Am J Hematol"},{"issue":"19","key":"3891_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u20131821","journal-title":"N Engl J Med"},{"issue":"4","key":"3891_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"9","key":"3891_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283\u20131294","journal-title":"Lancet Oncol"},{"issue":"6","key":"3891_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/14656566.4.6.889","volume":"4","author":"JT Hartmann","year":"2003","unstructured":"Hartmann JT, Lipp H-P (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4(6):889\u2013901","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"3891_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/10428190500178779","volume":"46","author":"L Alinari","year":"2005","unstructured":"Alinari L, Musuraca G, Tani M, Stefoni V, Gabriele A, Marchi E, Fina M, De Vivo A, Pileri S, Baccarani M (2005) Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 46(10):1437\u20131440","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"3891_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/A:1012501305214","volume":"12","author":"D Machover","year":"2001","unstructured":"Machover D, Delmas-Marsalet B, Misra S, Gumus Y, Goldschmidt E, Schilf A, Frenoy N, Emile J-F, Debuire B, Guettier C (2001) Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 12(10):1439\u20131443","journal-title":"Ann Oncol"},{"issue":"1","key":"3891_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-008-0847-y","volume":"64","author":"SJ Sym","year":"2009","unstructured":"Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C (2009) A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory\/relapsed aggressive non-Hodgkin\u2019s lymphoma. Cancer Chemother Pharmacol 64(1):27\u201333","journal-title":"Cancer Chemother Pharmacol"},{"key":"3891_CR19","doi-asserted-by":"crossref","unstructured":"Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM (2013) Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res","DOI":"10.1158\/1078-0432.CCR-13-1879"},{"key":"3891_CR20","unstructured":"Health UDo, Services H (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute 4 (03)"},{"issue":"5","key":"3891_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"1","key":"3891_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"issue":"3","key":"3891_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal C, O'Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30(3):253\u2013270","journal-title":"Comput Stat Data Anal"},{"issue":"5","key":"3891_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1023\/A:1026454831340","volume":"10","author":"J Aparicio","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, Pastor M (1999) ESHAP is an active regimen for relapsing Hodgkin\u2019s disease. Ann Oncol 10(5):593\u2013595","journal-title":"Ann Oncol"},{"issue":"10","key":"3891_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","volume":"93","author":"J Labrador","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, P\u00e9rez-L\u00f3pez E, Mateos MV, V\u00e1zquez L, Caballero MD, Garc\u00eda-Sanz R (2014) ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol 93(10):1745\u20131753","journal-title":"Ann Hematol"},{"issue":"6","key":"3891_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/14740338.2016.1179277","volume":"15","author":"E Oak","year":"2016","unstructured":"Oak E, Bartlett NL (2016) A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opin Drug Saf 15(6):875\u2013882","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"3891_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2328","volume":"35","author":"F Tixier","year":"2017","unstructured":"Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, Bouafia-Sauvy F, Sarkozy C, Tournamille J, Gyan E (2017) Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed\/refractory lymphoma patients. Hematol Oncol 35(4):584\u2013590","journal-title":"Hematol Oncol"},{"issue":"11","key":"3891_CR28","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1080\/10428190802441339","volume":"49","author":"R Rautert","year":"2008","unstructured":"Rautert R, Schink\u00f6the T, Franklin J, Weihrauch M, B\u00f6ll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D (2008) Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 49(11):2091\u20132098","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3891_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-9343(96)00352-X","volume":"102","author":"J Seymour","year":"1997","unstructured":"Seymour J, Talpaz M, Hagemeister F, Cabanillas F, Kurzrock R (1997) Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin\u2019s disease. Am J Med 102(1):21\u201328","journal-title":"Am J Med"},{"issue":"12","key":"3891_CR30","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","volume":"99","author":"BF Skinnider","year":"2002","unstructured":"Skinnider BF, Mak TW (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99(12):4283\u20134297","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03891-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:13:54Z","timestamp":1722266034000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03891-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03891-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"14 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided written informed consent before enrollment and the study was approved by our Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}